



In 2024, the Global Alliance for Patient Access promoted patient-centered care across five continents, addressing unmet needs through raising awareness and policy advocacy.

GAfPA's advocacy spanned not only the globe but also a variety of disease states, including respiratory conditions, chronic kidney disease, inflammation, cardiovascular disease and more.

The Global Alliance for Patient Access celebrated its 10-year anniversary in 2024. Supporting global, regional and national stakeholders—including policy-minded clinicians and patient advocates—GAfPA provided the capacity to ensure that health policy is informed by the perspectives of those on the frontlines of care.



#### **Raising Awareness**

From Mexico to Singapore, Geneva to Oman, GAfPA fostered conversations on the importance of cholesterol management, respiratory syncytial virus (RSV) prevention, remission in immune-mediated inflammatory conditions, blood health, policies to promote access to novel immunizations and innovative treatments.



#### **Building Alliances**

GAfPA served as secretariat of the Global Patient Alliance for Kidney Health, bringing together over 30 patient groups and key clinicians from across the globe to advocate for greater access to screening and early treatment for chronic kidney disease. Additionally, GAfPA partnered with stakeholders in Latin America, Europe and the Asia-Pacific region to increase access to clinical trials, raise awareness about rare and chronic diseases, and educate and mobilize physicians and advocates on patient access.




#### **Dispelling Misinformation**

GAfPA hosted forums to discuss the harm of medical misinformation, then developed and distributed resources to combat the social media skeptics fueling distrust about cholesterol management and vaccines. GAfPA sets the record straight with trusted resources informed by local stakeholders.

## **Digital Impact**

Throughout 2024, GAfPA's digital presence highlighted the lived experience of patients and providers in every corner of the globe. These metrics reflect the commitment and reach of GAfPA's work, from convening patient advocacy groups to persuading lawmakers to tackle pressing health care challenges.





GAfPA called for prioritizing better blood health by combatting anemia, a condition that affects 2 million people—predominantly women—and often accompanies chronic

disease. Patient blood management prioritizes the preservation and careful management of a patient's own blood across all stages of medical care, including screenings for anemia and iron deficiency as well as customizing treatment plans based on individual risk assessments.

Increased education, advocacy and solutions like patient blood management stand to strengthen clinical practices and improve patient outcomes. GAfPA worked to raise awareness on how a timely and coordinated global response can reduce the risks associated with iron deficiencies, anemia, blood loss and blood disorders.

#### **RESOURCES**



### One-Pager

Fast Facts: Chronic Disease, Anemia & Blood Health



- Empowering Patients on World AIDS Day: The Vital Role of Blood Health
- Understanding **Blood Health**



## Sharing patient stories and lived experiences is essential in making cardiovascular disease a priority for policymakers.

That was the key takeaway from roundtable discussions GAfPA hosted at the European Society of Cardiology and International Symposium on Atherosclerosis with cardiovascular stakeholders. The forums also tackled how advocates can push back on misinformation that is spreading online about cholesterol and cardiovascular disease.

Over the summer, GAfPA convened key cardiovascular disease advocates in Italy and Spain to discuss barriers impacting LDL cholesterol management and how localized awareness campaigns can improve access to screening and treatment. GAfPA also supported stakeholders in Canada to raise awareness about heart health and managing LDL cholesterol.

From cholesterol management to hypertension, GAfPA harnessed patient testimonies, global advocacy and awareness campaigns to reduce the global burden of cardiovascular disease, empowering patients to better advocate for themselves and communicate with their doctors.

#### **RESOURCES**



- Recap: International Symposium on Atherosclerosis
- European Society of Cardiology: **Event Emphasizes** the Importance of Combatting Cardiovascular Disease

## ( Videos

▶ Talking with your Health Care Provider about High **Blood Pressure** 



# Chronic kidney disease affects approximately 850 million people worldwide—more than 10% of the population.

This past year, GAfPA worked with partners and patient advocates to encourage policymakers to prioritize screenings, especially for at-risk populations. Earlier detection for CKD can be achieved through greater access to diagnostic screenings for vulnerable populations and a willingness from policymakers to treat CKD as a public health priority.

Alongside the World Health Assembly in Geneva, the Global Patient Alliance for Kidney Health convened its first-ever Chronic Kidney Disease Patient Forum. The event underscored the benefits of screening, early detection and elevating chronic kidney disease as a priority NCD.

#### **RESOURCES**

## **Events**

Kidney Health
 Stakeholders Call on
 World Health Assembly
 to Prioritize Screening
 and Early Detection

#### Videos

Make the Change for Kidney Health

## Policy Papers

Screening for Chronic Kidney Disease

## Blogs

- Know the Link: Diabetes and Chronic Kidney Disease on World Diabetes Day
- More Evidence
   Supports Making a
   Change for Kidney
   Health
- Make the Change for Kidney Health
- ▶ Kidney Health for All
- Kidney Health in Times of Crisis



Clinical trials are critical to providing the next generation of cures and treatments. But for too long, clinical trials have suffered from a lack of awareness and participation, especially in low- and middle-income countries.

Encouraging investment in clinical trials is an essential part of patient care. By testing new treatments, clinical trials drive innovative research and connect patients with transformative medicine. GAfPA continues to work with health care providers, patient advocates and policymakers to raise awareness and foster participation in clinical trials around the world.

#### **RESOURCES**



Webinar: Clinical Trials in Latin America

## Policy Brief

 Patient Access to Clinical Trials in Latin America



RSV is a common respiratory virus that most children get by age two. While symptoms are often mild, RSV poses a significant threat to infants, especially those under six months, as well as older adults. Severe cases can lead to bronchiolitis or pneumonia, often resulting in hospitalizations and long-term complications.

GAfPA convened RSV stakeholders in Brazil and Mexico to discuss the burden and impact on infants and how raising awareness can improve patient outcomes and access to new prevention options.

In 2024, GAfPA released a report synthesizing lessons learned from the COVID-19 pandemic to carve a pathway of protection from infectious respiratory diseases in Europe. Drawing from years of advocacy and sound evidence of life-saving measures, GAfPA encouraged policymakers to enhance timely communications, invest in coordinated vaccination campaigns and increase ground-level involvement.

#### **RESOURCES**




## Report

Infectious Respiratory Disease in Europe: The Pathway to Protection



- World Immunization Day: Protecting Health, Preventing Disease
- October Marks RSV Awareness Month



▶ What is RSV? (em português)



## Remission, the absence of disease signs and symptoms, is possible for many patients struggling with inflammatory rheumatic diseases.

GAfPA encourages remission as the goal for providers and patients living with inflammatory rheumatic conditions. With prioritization of optimal care, treatment and timely diagnosis, patients can achieve a better quality of life.

In 2024, GAfPA was the preeminent organization working to convene stakeholders to overcome the barriers to remission. GAfPA produced an evidence glossary in seven languages that summarizes current research on inflammatory arthritis and the value of remission.

Additionally, GAfPA convened advocates in Singapore to highlight the importance of shared decision-making. Attendees stressed that providing clear, evidence-based information helps patients better understand their conditions and treatment options and enables patients to collaborate more effectively with their health care providers.

#### **RESOURCES**



#### **Events**

- ▶ The Value of Remission: An Advocacy Roundtable Summary in Singapore
- ▶ The Value of Remission: An Advocacy Roundtable Summary in Austria

## Reports

- ▶ The Value of Achieving Remission in Inflammatory **Rheumatic Conditions**
- ▶ The Value of Achieving Remission in Inflammatory Rheumatic Conditions: An Evidence Glossary

## **Blogs**

- Recap: The Value of Achieving Remission in Inflammatory Rheumatic Diseases
- ▶ Health Care Advocates Convene in Singapore
- World's First Evidence Glossary Quantifies the Impact of Inflammatory **Rheumatic Conditions**



## Patient-centered care has never been more important.

In 2025, GAfPA will continue its advocacy efforts to support policies that promote patient-centered care, prioritize early screening and improve access to treatment.

GAfPA looks forward to engaging with patients and policymakers across the globe to strengthen partnerships, increase education and promote better patient care for all.



# About the Global Alliance for Patient Access

The Global Alliance for Patient Access is an international platform for health care providers and patient advocates to inform policy dialogue about patient-centered care.

**GAfPA.org** 



